Navigation Links
Abaxis, Inc. CEO to Present at the Eighth Annual Forbes Global CEO Conference in Singapore
Date:9/2/2008

UNION CITY, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, CEO and President, will participate in the Forbes Global CEO Conference "Best Under a Billion" panel on Tuesday, September 9, 2008 at the Shangri-La Hotel in Singapore.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Contact: Clint Severson Lytham Partners, LLC

Chief Executive Officer Joe Dorame, Joe Diaz & Robert Blum

ABAXIS, Inc. 602-889-9700

510-675-6500


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Abaxis, Inc. to Present at the Fifth Annual Sidoti & Company Emerging Growth Conference
2. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. Abaxis, Inc. to Present at the Sidoti & Company Twelfth Annual New York Emerging Growth Institutional Investor Forum
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... from the University of Melbourne said this small increase ... benefits from CT scans in diagnosing and monitoring disease. ... British Medical Journal today and involved researchers at ... International Agency for Research on Cancer in Lyon, France. ... useful in providing detailed three dimensional pictures to diagnose ...
(Date:5/22/2013)... King of Prussia, PA (PRWEB) May 22, 2013 ... is proud to announce its participation in the Greater Philadelphia ... experienced cyclists and recreational riders who are passionate about stopping ... affects more than 25 million Americans. , The Tour ... Ambler Campus, located at 580 Meetinghouse Road in Ambler, 30 ...
(Date:5/22/2013)... 22, 2013 CoCENTRIX, a leading ... Health and Human Services and community providers, announced ... (ADMH) selected the CoCENTRIX Coordinated Care Platform ... the Health Records and coordinate care within and ... , CoCENTRIX is transitioning the hospitals' official records ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Hypervibe, a ... machines , announced today that the company’s US division ... Sunday, and Monday. Military personnel ordering the Hypervibe Performance ... when they show a valid military ID. Non-military customers ... that values commitment, honor, and integrity. These are values ...
(Date:5/22/2013)... Chicago, IL (PRWEB) May 22, 2013 ... and are looking for education on how to lose ... thresholds can be challenging and may demotivate people to ... A new study discussed this week on Medical ... that learning how to lose weight and actually losing ...
Breaking Medicine News(10 mins):Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3Health News:Hypervibe Whole Body Vibration Offers First-Ever Sale This Memorial Day Weekend 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Break the Cycle of Obesity and Weight Gain With New Education For Patients on How to Lose Weight the Healthy Way 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Break the Cycle of Obesity and Weight Gain With New Education For Patients on How to Lose Weight the Healthy Way 3
... researcher has co-authored an international study that revealed a drug ... a rare lung disease in women. The life-threatening disease ... The clinical trial of the drug -- called sirolimus -- ... therapy for the lung disease, lymphangioleiomyomatosis, or LAM. LAM ...
... The wrist size of overweight or obese children and teens ... says a new study. Italian researchers measured the wrist ... They also used a painless nuclear imaging technique on about ... areas of the wrist more precisely. Blood tests were ...
... MONDAY, April 11 (HealthDay News) -- A drug commonly prescribed ... treating the mild stage of the disease, a new study ... effective in treating moderate to severe Alzheimer,s disease, "in mild ... works," said lead researcher Dr. Lon S. Schneider, a professor ...
... new discovery published online in The FASEB Journal ( ... likely to benefit from breast cancer drug therapies. If ... it would represent a significant advance for breast cancer ... some people. In addition, some drugs have side effects ...
... How your carotid artery moves can reveal your risk of ... study this vessel aspect in more detail thanks to a ... with suspected coronary artery disease, reveals a thesis from the ... arteries is associated with a risk of future heart disease, ...
... the journal Investigational New Drugs and conducted by researchers ... molecule inhibitors are showing promise in blocking STAT3, a ... osteosarcoma. These small molecule inhibitors one derived from ... as a new, non-toxic treatment for these deadly tumors. ...
Cached Medicine News:Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Drug Memantine Ineffective for Mild Alzheimer's, Study Finds 2Health News:Drug Memantine Ineffective for Mild Alzheimer's, Study Finds 3Health News:Tiny antibody fragments raised in camels find drug targets in human breast cancer cells 2Health News:New potential atherosclerosis risk marker discovered 2Health News:New study finds compounds show promise in blocking STAT3 signaling as treatment for osteosarcoma 2
(Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013  OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...
(Date:5/21/2013)... , May 21, 2013 Reaching a ... process, the National Association of Boards of Pharmacy ® ... the .PHARMACY domain suffix has passed the Internet Corporation ... intends to launch the .PHARMACY gTLD by the end ... to legitimate online pharmacies and related entities that are ...
(Date:5/21/2013)... SAN FRANCISCO , May 21, 2013 /PRNewswire/ ... meeting of the American Psychiatric Association show that ... statistically and clinically meaningful response and remission in ... acute phase of therapy, which were maintained through ... acute treatment, 62 percent of patients achieved symptomatic ...
Breaking Medicine Technology:OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
... of Gastroenterology Annual ... ... two Phase 3,studies presented at the American College of Gastroenterology Annual,Scientific ... rates than lansoprazole among patients with more,severe grades of erosive esophagitis ...
Cached Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: